Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 2/20 | 0.69 |
| ▸ | RAF1 | P04049 | 8/20 | 0.56 |
| ▸ | CSF1R | P07333 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | KDR | P35968 | 3/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | BRAF | P15056 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13603633 | 0.93 | DDR2 (0.70) | DDR2RAF1CSF1RALDH1A1KDR | |
| SCHEMBL171217 | 0.93 | DDR2 (0.70) | DDR2RAF1CSF1RALDH1A1KDR | |
| SCHEMBL17000078 | 0.91 | DDR2 (0.82) | DDR2RAF1CSF1RALDH1A1KDR | |
| SCHEMBL17000012 | 0.91 | DDR2 (0.62) | DDR2RAF1CSF1RKDREPHX2 | |
| SCHEMBL17000002 | 0.91 | DDR2 (0.60) | DDR2RAF1CSF1RKDREPHX2 | |
| SCHEMBL13603627 | 0.90 | DDR2 (0.70) | DDR2RAF1CSF1RALDH1A1KDR | |
| SCHEMBL15574556 | 0.90 | DDR2 (0.70) | DDR2RAF1CSF1RALDH1A1KDR | |
| SCHEMBL171194 | 0.89 | DDR2 (0.67) | DDR2RAF1CSF1RALDH1A1KDR | |
| SCHEMBL15573077 | 0.88 | DDR2 (0.65) | DDR2RAF1CSF1RALDH1A1KDR | |
| SCHEMBL17000035 | 0.88 | DDR2 (0.57) | DDR2RAF1CSF1RKDREPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | MERCK PATENT GMBH (DE) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225369-A1 | DDR2 INHIBITORS FOR THE TREATMENT OF OSTEOARTHRITIS | DDR2, DDR1, DDRGK1 | DDR2 1/4885RAF1 3072/4885CSF1R 885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.